Acquisition of CorHepta (Additional Information) (Details) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
Feb. 21, 2026 |
Feb. 21, 2025 |
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Business Combination [Line Items] | ||||
| Shares vested | 2,489,545 | 4,149,252 | ||
| Shares Unvested | 4,149,252 | 4,149,252 | ||
| Shares forfeited | 1,660,222 | |||
| Change in fair value contingent consideration | $ 4,435,443 | $ 373,354 | $ 1,164,864 | |
| Written off | 7,357,294 | |||
| CorHepta Pharmaceuticals [Member] | ||||
| Business Combination [Line Items] | ||||
| Date of acquisition agreement | Feb. 21, 2025 | |||
| Change in fair value contingent consideration | 373,354 | $ 1,164,864 | ||
| Consideration transferred | $ 7,400,000 | |||
| CorHepta Pharmaceuticals [Member] | Common Stock | ||||
| Business Combination [Line Items] | ||||
| Issuance of common stock, Shares | 4,979,101 | |||
| Shares vested | 829,849 | 829,849 | ||
| Shares representing contingent consideration | 2,489,030 | 1,493,415 | ||
| Shares representing post-merger compensation expense | 1,660,222 | |||
| Shares Unvested | 1,493,415 | |||
| X | ||||||||||
- Definition Change In Fair Value Contingent Consideration No definition available.
|
| X | ||||||||||
- Definition Shares Representing Contingent Consideration No definition available.
|
| X | ||||||||||
- Definition Shares Representing Post-Merger Compensation Expense No definition available.
|
| X | ||||||||||
- Definition Shares Unvested On Acquisition No definition available.
|
| X | ||||||||||
- Definition Shares Vested on Acquisition No definition available.
|
| X | ||||||||||
- Definition Written off As Research And Development Expense No definition available.
|
| X | ||||||||||
- Definition Date when acquisition agreement is executed in business combination, in YYYY-MM-DD format. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares (or other type of equity) forfeited during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|